OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages

Abstract

BackgroundDespite recent advances in colorectal cancer (CRC) diagnosis and population screening programs, the identification of patients with preneoplastic lesions or with early CRC stages remains challenging and is important for reducing CRC incidence and increasing patient’s survival. MethodsWe analysed 76 colorectal tissue samples originated from early CRC stages, normal or inflamed mucosa by label-free proteomics. The characterisation of three selected biomarker candidates was performed by immunohistochemistry on an independent set of precancerous and cancerous lesions harbouring increasing CRC stages.ResultsOut of 5258 proteins identified, we obtained 561 proteins with a significant differential distribution among groups of patients and controls. KNG1, OLFM4 and Sec24C distributions were validated in tissues and showed different expression levels especially in the two early CRC stages compared to normal and preneoplastic tissues.ConclusionWe highlighted three proteins that require further investigations to better characterise their role in early CRC carcinogenesis and their potential as early CRC markers.Electronic supplementary materialThe online version of this article (doi:10.1186/s12014-017-9143-3) contains supplementary material, which is available to authorized users.

Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer

“…20 The OLFM4 gene has been analyzed as a putative biomarker in many cancers, including gastrointestinal cancer, head and neck squamous cell carcinoma, cervical neoplasia, nonsmall cell lung cancer, triple-negative breast cancer and distant metastases in estrogen receptor-positive breast carcinoma. [20][21][22][23][24][25][26][27][28][29][30][31][32] In our study, we provide clinical evidence that reduced OLFM4 expression was associated with prostate cancer progression and with DNA methylation of CpG sites in the OLFM4 gene promoter region in human prostate adenocarcinoma. We also found that OLFM4 may play a role in regulating EMT, as well as tumor initiation and growth, in prostate cells.…”

“…In addition, DNA methylation of the OLFM4 gene has been found to be associated with tumor aggressiveness and patient outcomes in gastric carcinoma . The OLFM4 gene has been analyzed as a putative biomarker in many cancers, including gastrointestinal cancer, head and neck squamous cell carcinoma, cervical neoplasia, nonsmall cell lung cancer, triple‐negative breast cancer and distant metastases in estrogen receptor‐positive breast carcinoma …”

Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance

“…Coupled with label-free shotgun proteomics and immunohistochemistry, these FFPE tissues have been widely used to identify biomarkers and drug targets in different disease settings [22], [23], [24], [25]. Several recent reports highlight a limited correlation between mRNA levels and corresponding protein levels, thus arguing in favor of proteomic approaches [26], [27].…”

Development of Prognostic Signature Based on Pan-cancer Proteomics

“…Hence, tumor tissues would regulate the expression of proteins and promote the production of proteins associated with cancer progression. 7 Moreover, proteins were the functional effectors of cellular processes as well as the targets for a vast majority of therapeutics. 8 Therefore, the study of proteomics can improve our understanding of cancer aetiology and progression as well as heighten the assessment of cancer prognosis.…”